Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2026 [3]. - The lawsuit alleges that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the prospects of its INO-3107 Biologics License Application [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Inovio Pharmaceuticals, Inc. Stock Alert: INO Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses [Accessibility Statement] Skip NavigationSAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- [Robbins LLP] reminds stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focu ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Faruqi ...

PresentationHello, everyone, and welcome to Oppenheimer's 36th Annual Life Science Conference. I'm Jay Olson, one the biotech analysts here at Oppenheimer, and it's a pleasure to welcome you to our discussion with Inovio Pharmaceuticals. And it's an honor to introduce Jacqui Shea, the CEO; and Mike Sumner, the CMO of Inovio. With that, I'll turn it over to you, Jacqui, for a few slides to set up our discussion before we start to fireside. And thank you so much for joining us here today.Jacqueline SheaCEO, P ...

Inovio Pharmaceuticals FY Conference Summary Company Overview - **Company**: Inovio Pharmaceuticals (NasdaqCM: INO) - **Focus**: Developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [4][5] - **Lead Candidate**: INO-3107, targeting recurrent respiratory papillomatosis (RRP) caused by HPV 6 and 11 [4][5] Regulatory Updates - **BLA Acceptance**: INO-3107's Biologics License Application (BLA) accepted for review by the FDA under the Accelerated Approval Program with a PDUFA target date of October 30, 2026 [5][19] - **Designations**: Received Orphan Drug designation and Breakthrough Therapy designation from the FDA and Orphan Drug designation in the EU [5] - **Regulatory Challenges**: Disappointment over not receiving priority review; FDA indicated inadequate information for Accelerated Approval eligibility [19][20] Market Opportunity - **RRP Prevalence**: Approximately 14,000 active cases in the U.S., with potential underestimation of market opportunity [12][39] - **Surgery Burden**: Patients may require hundreds of surgeries over a lifetime, leading to significant unmet needs [12][13] - **Competitor Pricing**: Competitor's treatment priced at approximately $115K per dose, indicating a lucrative market for RRP treatments [39] Product Profile and Efficacy - **Efficacy Data**: INO-3107 shows a 50%-100% reduction in surgeries after treatment, with 72% in year 1 improving to 86% in year 2; 28% of patients required no surgeries in year 1, increasing to 50% in year 2 [14][15] - **Safety Profile**: Well-tolerated with transient injection site reactions; no treatment discontinuations reported [15] - **Administration**: Office-based administration with no need for ultra-cold chain storage, making it easier for healthcare professionals [16] Clinical Pipeline - **Future Trials**: Plans to initiate Phase III trial for INO-3112 and Phase II trial for INO-5401 in glioblastoma; advancing DPROT platform candidates from preclinical to Phase I [17][41] - **dMAb Technology**: Exciting early-stage technology with potential to unlock further applications of DNA medicines [6][41] Immunogenicity and Redosing Strategy - **Comparison with Adenoviral Approaches**: INO-3107 avoids generating immune responses against viral vectors, allowing for multiple redosing without the risk of neutralizing antibodies [35][36][38] - **Redosing Plans**: Potential annual redosing strategy post-approval to maintain cytotoxic T-cell responses [38] Upcoming Milestones - **PDUFA Date**: Focus on the upcoming PDUFA date in October 2026; awaiting FDA meeting to discuss preliminary comments [17][43] - **Market Research**: Ongoing research to support launch strategy and address unmet needs in the RRP community [39][40] Conclusion - Inovio Pharmaceuticals is positioned to address significant unmet needs in the RRP market with its lead candidate INO-3107, supported by promising efficacy and safety data. The company is actively engaging with regulatory bodies to navigate the approval process while also advancing its broader clinical pipeline.

Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit [Accessibility Statement] Skip NavigationLOS ANGELES, Feb. 25, 2026 /PRNewswire/ -- [The Law Offices of Frank R. Cruz] announces that investors with losses related to Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: [INO]) have opportunity to lead the securities fraud class action lawsuit.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INOVIO PHARMACEUTICALS, INC. (INO), CLICK [HER ...

LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION [Accessibility Statement] Skip NavigationShareholders Who Purchased INO Securities During Class Period Urged to Review OptionsNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO).YOU MAY BE AFFECTED IF YOU:- Acquired shares during the Class Period- Lost money on your Inovio inves ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its CELLECTRA device and the INO-3107 Biologics License Application [2][5]. Allegation Details - The lawsuit claims that during the Class Period, Inovio made false statements about the manufacturing quality of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [5]. - It is alleged that Inovio lacked sufficient information to support the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [5]. - The lawsuit asserts that when the true information became public, investors suffered financial damages, particularly after the FDA's announcement regarding the BLA's acceptance on a standard review timeline rather than accelerated approval [5]. Stock Price Impact - Following the FDA's announcement on December 29, 2025, Inovio's stock price dropped by $0.56 per share, representing a decline of 24.45%, closing at $1.73 per share [5].

BENSALEM, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to howardsmith@howardsmithla ...

Investors in Inovio Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before April 7, 2026 to Discuss Your Rights - INO [Accessibility Statement] Skip NavigationNEW YORK, Feb. 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inovio Pharmaceuticals, Inc. (NASDAQ: INO).Shareholders who purchased shares of INO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not requi ...